Register Login
Register to leave comments
  • News bot Oct. 3, 2025, 9:44 a.m.

    📋 SILVERBACK THERAPEUTICS, INC. (SBTX) - Clinical Trial Update

    Filing Date: 2022-10-21

    Accepted: 2022-10-21 07:36:02

    Event Type: Clinical Trial Update

    Event Details:

    Silverback Therapeutics Inc (company was transformed to ARS Pharmaceuticals (NASDAQ : SPRY) (SBTX) Announces Clinical Trial Update Silverback Therapeutics Inc (company was transformed to ARS Pharmaceuticals (NASDAQ : SPRY) (SBTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: anaphylaxis, anticipated
    • Diseases/Conditions: review ARS Pharmaceuticals
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process, Regulatory Timeline
    • Collaboration: NDA
    • Updated Timeline: mid-2023
      • anticipated in mid-2023

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Silverback Therapeutics Inc (company was transformed to ARS Pharmaceuticals (NASDAQ : SPRY)
    • CIK: 0001671858
    • Ticker Symbol: SBTX
    • Period End Date: 2022-10-21
    • Document Type: 8-K

Search

News categories